1
|
Kumar N, Ehsan S, Banerjee S, Fernandez Perez C, Lhuilier I, Neuner J, Friebel-Klingner T, Fayanju OM, Nair B, Niinuma SA, Nampoothiri S, McCarthy AM. The unique risk factor profile of triple-negative breast cancer: a comprehensive meta-analysis. J Natl Cancer Inst 2024; 116:1210-1219. [PMID: 38445713 PMCID: PMC11308168 DOI: 10.1093/jnci/djae056] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/26/2023] [Revised: 01/24/2024] [Accepted: 02/29/2024] [Indexed: 03/07/2024] Open
Abstract
BACKGROUND Triple-negative breast cancer (TNBC) has a poor prognosis compared with other breast cancer subtypes. This systematic review and meta-analysis examines whether known risk factors for breast cancer are also associated with TNBC in adult women. METHODS EMBASE, Medline, SCOPUS, and gray literature were queried with no limit on the date or language of publication. The exposures of interest included parity, breastfeeding, duration of breastfeeding, age at menarche, age at first live birth, oral contraceptive (OC) use, duration of OC use, use of menopausal hormone therapy (MHT), family history, body mass index (BMI), alcohol use, smoking, and breast density. The main outcome of interest was TNBC. Study quality was determined using the Newcastle-Ottawa scale for case control studies and cohort studies. We estimated weighted odds ratios from random effects models to study the exposure-outcome associations. Protocol was registered under the number: PROSPERO 2021 CRD42021254594. RESULTS Thirty-three studies were included. Family history, longer duration of OC use, and higher breast density were significantly associated with increased risk for TNBC, whereas later age at menarche, later age at first birth, and breastfeeding were protective against TNBC. Parity, MHT, alcohol, smoking, and BMI were not significantly associated with TNBC overall, but higher parity was associated with higher risk among Black women. CONCLUSION Our findings highlight that TNBC has a distinct risk factor profile compared with overall breast cancer. This can be the foundational work in identification of actionable TNBC risk factors to improve prevention and early detection of these poor prognosis breast tumors.
Collapse
Affiliation(s)
- Nitya Kumar
- Department of Medicine, Royal College of Surgeons in Ireland - Bahrain, Busaiteen, Bahrain
| | - Sarah Ehsan
- Department of Biostatistics, Epidemiology & Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
| | - Shahana Banerjee
- Department of Biostatistics, Epidemiology & Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
| | - Claudia Fernandez Perez
- Department of Biostatistics, Epidemiology & Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
| | - Isabelle Lhuilier
- Department of Biostatistics, Epidemiology & Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
| | - Jillian Neuner
- Department of Biostatistics, Epidemiology & Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
| | - Tara Friebel-Klingner
- Department of Epidemiology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, USA
| | - Oluwadamilola M Fayanju
- Department of Biostatistics, Epidemiology & Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
| | - Bindhu Nair
- Department of Medicine, Royal College of Surgeons in Ireland - Bahrain, Busaiteen, Bahrain
| | - Sara Anjum Niinuma
- Department of Medicine, Royal College of Surgeons in Ireland - Bahrain, Busaiteen, Bahrain
| | | | - Anne Marie McCarthy
- Department of Biostatistics, Epidemiology & Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
| |
Collapse
|
2
|
Cao J, Li J, Zhang Z, Qin G, Pang Y, Wu M, Gu K, Xu H. Interaction between body mass index and family history of cancer on the risk of female breast cancer. Sci Rep 2024; 14:4927. [PMID: 38418549 PMCID: PMC10901816 DOI: 10.1038/s41598-024-54762-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/12/2023] [Accepted: 02/16/2024] [Indexed: 03/01/2024] Open
Abstract
Both body mass index (BMI) and family history of cancer are established risk factors for female breast cancer. However, few studies explored the potential interaction between both factors. We assessed the association of BMI and its interaction with family cancer history on the risk of female breast cancer in Shanghai, China. Based on a population-based prospective cohort study started from 2008 to 2012 with 15,055 Chinese female participants in Minhang district, Shanghai. Cox regression models were used to estimate the association of BMI and its interaction with a family history of cancer on breast cancer risk. The additive interaction was evaluated by the relative excess risk due to interaction (RERI) and the attributable proportion due to interaction (AP), and the multiplicative interaction was assessed by the product term (BMI* family history of cancer) in the Cox regression model. Compared with BMI of < 24 kg/m2 and no family history of cancer, women with BMI of ≥ 24 kg/m2 and a family history of cancer had a higher risk for breast cancer with HR 2.06 (95% CI 1.39, 3.06). There was an additive interaction between BMI and family history of cancer on breast cancer incidence, with the RERI being 0.29 (95% CI 0.08, 0.51) and the AP being 0.37 (95% CI 0.08, 0.66). The coexistence of obesity and cancer family history may exacerbate breast cancer incidence risk, highlighting the importance of weight management in women with a family history of cancer.
Collapse
Affiliation(s)
- Jiamin Cao
- Shanghai Minhang Center for Disease Control and Prevention, No. 965, Zhongyi Road, Shanghai, 201101, China
- Shanghai Municipal Center for Disease Control and Prevention, No. 1380, Zhongshan West Road, Shanghai, 200336, China
| | - Jun Li
- Shanghai Minhang Center for Disease Control and Prevention, No. 965, Zhongyi Road, Shanghai, 201101, China
| | - Zuofeng Zhang
- Department of Epidemiology, Fielding School of Public Health, University of California, Los Angeles, CA, USA
| | - Guoyou Qin
- School of Public Health, Fudan University, Shanghai, China
| | - Yi Pang
- Shanghai Municipal Center for Disease Control and Prevention, No. 1380, Zhongshan West Road, Shanghai, 200336, China
| | - Mengyin Wu
- Shanghai Municipal Center for Disease Control and Prevention, No. 1380, Zhongshan West Road, Shanghai, 200336, China
| | - Kai Gu
- Shanghai Municipal Center for Disease Control and Prevention, No. 1380, Zhongshan West Road, Shanghai, 200336, China.
| | - Huilin Xu
- Shanghai Minhang Center for Disease Control and Prevention, No. 965, Zhongyi Road, Shanghai, 201101, China.
| |
Collapse
|
3
|
Huq MR, Woodard N, Okwara L, Knott CL. Breast Cancer Educational Needs and Concerns of African American Women Below Screening Age. JOURNAL OF CANCER EDUCATION : THE OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER EDUCATION 2022; 37:1677-1683. [PMID: 33932194 DOI: 10.1007/s13187-021-02012-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Accepted: 04/13/2021] [Indexed: 06/12/2023]
Abstract
African American women are disproportionately impacted by breast cancer, including triple-negative disease, at a young age. Yet most public health research in breast cancer focuses on women of screening age. This study identified the specific breast cancer educational needs of African American women below the recommended screening age. Data were collected through 30 key informant interviews with young African American women breast cancer survivors (diagnosed between 18 and 45), family members of African American women diagnosed between 18-45 years, and community organization leaders and healthcare providers who work with young African American women impacted by breast cancer. Data were coded and analyzed by multiple team members using template analysis. The analysis identified four overarching themes reflecting breast cancer educational needs of young African American women. Although most Breast Cancer Knowledge and Perceived Risk educational needs were consistent with those of older women, there were specific needs involving Cultural Reluctance in Health Disclosures and Breast Cancer Risk Reduction. With regard to Healthcare Provider Relationships, participants stated a need for younger women to be particularly proactive in advocating for their health, as providers may be dismissive about cancer concerns due to young age. Though breast cancer in younger women is statistically improbable, there are educational needs specific to young African American women involving self-advocacy and family history. Findings have implications for developing interventions guiding young women to advocate for themselves in medical encounters and in their families, as well as for teaching medical providers how to counsel the young women regarding breast cancer.
Collapse
Affiliation(s)
- Maisha R Huq
- Department of Behavioral and Community Health, School of Public Health, University of Maryland-College Park, 4200 Valley Drive, College Park, MD, 20742, USA.
| | - Nathaniel Woodard
- Department of Behavioral and Community Health, School of Public Health, University of Maryland-College Park, 4200 Valley Drive, College Park, MD, 20742, USA
| | - Leonore Okwara
- Department of Behavioral and Community Health, School of Public Health, University of Maryland-College Park, 4200 Valley Drive, College Park, MD, 20742, USA
| | - Cheryl L Knott
- Department of Behavioral and Community Health, School of Public Health, University of Maryland-College Park, #1234W 4200 Valley Drive, College Park, MD, 20742, USA
| |
Collapse
|
4
|
Sithole N, Ginindza TG, Somdyala NIM. Distribution and trends of cancer in Buffalo City, Eastern Cape Province, 1991-2009: a retrospective study. Pan Afr Med J 2022; 42:301. [PMID: 36425547 PMCID: PMC9653547 DOI: 10.11604/pamj.2022.42.301.30575] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/29/2021] [Accepted: 09/30/2021] [Indexed: 09/08/2024] Open
Abstract
Despite interventions, cancer remains a global public health concern. Cancer burden continues to grow globally, demanding the implementation of important preventative and control initiatives. Informative reports on existing routine cancer data are therefore required. This study describes the distribution and trends of cancer in Buffalo City (BFC) population, Eastern Cape (EC) Province for the period 1991-2009. Cancer patients were retrospectively surveyed in the database of Frere Hospital Oncology-Radiation Unit. Proportion by sex, race, geographical distribution in the province and top cancer sites were calculated. Direct method of standardisation was used to calculate Age Standardised Rates (ASR) for a subpopulation of patients residing at BFC; age-specific rates were applied to the reference population (World Standard Population). Trends in rates with 95% Confidence Intervals (CI) for two most common cancers in males and females over time adjusted for age and sex and interactions between time and race were assessed using Poisson Regression. A total of 19 737 patients´ records were analysed; 38.8% (7 656) males and 61.2% (12 081) females. Most patients were Black Africans (81.5%), followed by Whites (13.5%), Mixed Race (4.5%) and Asians (0.5%). A larger proportion (46.0%) of the patients were from Buffalo City, while the rest were distributed in other municipalities served by Frere Hospital. Top five cancers in males were lung [22.5%, ASR 21.0], prostate [14.7%, ASR 9.2], larynx [5.8%, ASR 5.0], mouth [4.4%, ASR 3.7] and tongue [3.8%, ASR 2.9 per 100 000] in females; cervix [20.9%, ASR 23.0], breast [23.6%, ASR 20.2], lung [3.4%, ASR 4.7], ovary [2.1%, ASR 3.0] and corpus uteri [3.4%, ASR 2.8]. Trends showed a decrease in lung and prostate cancers in males, while cervix and breast remained stable in females. White males were two times (95% CI: 1.87-2.49) more likely to have lung cancer and five times (95% CI: 3.90-6.21) more likely to have prostate cancer than Black Africans. White females were 0.43 (95% CI: 0.44-0.73) less likely to have cervical cancer and three times (95% CI: 2.45-3.14) more likely to have breast compared to Black Africans. In conclusion, the availability of routine cancer data at Frere Hospital contributes to strengthening of the national cancer notification regulation, as the results of this study suggest that the burden of cancer in the EC Province remains high.
Collapse
Affiliation(s)
- Nomfuneko Sithole
- South African Medical Research Council, Burden of Disease Research Unit, Francie van Zijl Drive, Parow Valley, Cape Town, 7505, South Africa
| | - Themba Geoffrey Ginindza
- Discipline of Public Health Medicine, School of Nursing and Public Health, University of KwaZulu-Natal, South Africa
| | - Nontuthuzelo Iris Muriel Somdyala
- South African Medical Research Council, Burden of Disease Research Unit, Francie van Zijl Drive, Parow Valley, Cape Town, 7505, South Africa
| |
Collapse
|
5
|
Jakuboski SH, McDonald JA, Terry MB. Do current family history-based genetic testing guidelines contribute to breast cancer health inequities? NPJ Breast Cancer 2022; 8:36. [PMID: 35319016 PMCID: PMC8941019 DOI: 10.1038/s41523-022-00391-4] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/24/2021] [Accepted: 01/11/2022] [Indexed: 02/03/2023] Open
Abstract
Prior to the recommended age for population-based breast cancer screening by mammography, which ranges from 40-50 years depending on guidelines, the main way to identify higher risk women for earlier breast cancer (BC) screening to improve outcomes and discuss targeted chemoprevention is through specific clinical guidelines which are largely based on family history of breast cancer and known mutations in breast cancer susceptibility genes. The annual percent change (APC) in early-onset BC continues to rise, with the higher early-onset cancer burden and mortality continuing to be seen in non-Hispanic black (NHB) women compared to non-Hispanic white (NHW) women. Coupled with the increasing incidence overall as well as the lower percent of BC family history reported in NHB women compared with that of NHW women means that continued reliance on guidelines to identify women for genetic screening and initiation of early BC screening based largely on family history could lead to even greater BC health inequities. The similarity in the prevalence of mutations in key BC susceptibility genes between NHB and NHW women contrasts sharply to the differences in age-specific incidence rates between NHB and NHW women, supporting that there must be environmental modifiers that are contributing to the increased incidence in NHB women. This reality further argues for identifying NHB women early in adulthood through genetic testing who may benefit from tailored BC risk-reduction programs and early BC screening.
Collapse
Affiliation(s)
| | - Jasmine A McDonald
- Mailman School of Public Health, Columbia University Irving Medical Center, New York, NY, 10032, USA
- Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, NY, 10032, USA
| | - Mary Beth Terry
- Mailman School of Public Health, Columbia University Irving Medical Center, New York, NY, 10032, USA.
- Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, NY, 10032, USA.
| |
Collapse
|
6
|
Huq MR, Woodard N, Okwara L, McCarthy S, Knott CL. Recommendations for breast cancer education for African American women below screening age. HEALTH EDUCATION RESEARCH 2022; 36:530-540. [PMID: 34533195 DOI: 10.1093/her/cyab033] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/17/2021] [Accepted: 08/27/2021] [Indexed: 06/13/2023]
Abstract
Although statistically unlikely, early-onset breast cancer tends to be more aggressive and leads to greater mortality than breast cancer among women of screening age. Young African American women are disproportionately impacted by early-onset breast cancer compared to women of other races. Given the racial disparities and because young women are typically not the primary audience for breast cancer educational messaging, there is a need to identify recommendations for age-appropriate breast cancer education for African American women below mammogram eligibility. Through N = 30 key informant interviews with young African American breast cancer survivors, family members of young survivors, community organization leaders and healthcare providers, we identified breast cancer educational message content and communication channels relevant for these women. Participants recommended that message content should emphasize the need to address family cancer history and self-advocacy in healthcare encounters in addition to concerns about loss of womanhood, financial costs and opportunity costs associated with preventive healthcare visits. Breast cancer messages for this audience should consider the influences of earlier life stage, culture and race. Recommended communication channels highlighted use of social media and videos. Findings will inform future age-appropriate educational messaging aimed at eliminating early-onset breast cancer disparities disproportionately impacting young African American women.
Collapse
|
7
|
Sha R, Xu Y, Yuan C, Sheng X, Wu Z, Peng J, Wang Y, Lin Y, Zhou L, Xu S, Zhang J, Yin W, Lu J. Predictive and prognostic impact of ferroptosis-related genes ACSL4 and GPX4 on breast cancer treated with neoadjuvant chemotherapy. EBioMedicine 2021; 71:103560. [PMID: 34482070 PMCID: PMC8417304 DOI: 10.1016/j.ebiom.2021.103560] [Citation(s) in RCA: 60] [Impact Index Per Article: 20.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/28/2021] [Revised: 08/08/2021] [Accepted: 08/15/2021] [Indexed: 01/15/2023] Open
Abstract
BACKGROUND Recent evidence shows that inducing ferroptosis may improve efficacy of tumor therapy. However, ferroptosis-related genes have been little studied in patients with breast cancer especially in the neoadjuvant setting. ACSL4 and GPX4 have been well established as the positive and negative regulator of ferroptosis, respectively. This study aimed to explore the predictive value of ACSL4 and GPX4 for patients with breast cancer administered neoadjuvant chemotherapy. METHODS This study included patients treated with paclitaxel-cisplatin-based neoadjuvant chemotherapy. Immunohistochemistry staining of ACSL4 and GPX4 was carried out on the core needle biopsy specimens. Logistic regression was performed to explore the predictive biomarkers of pathological complete response (pCR). Survival analyses were examined by log-rank test and Cox proportional hazard regression. FINDINGS A total of 199 patients were included for the analyses. Both ACSL4 expression and ACSL4/GPX4 combination status could serve as independent predictive factors for pCR. The interaction for pCR was observed between ACSL4 and clinical tumor stage. Besides, ACSL4 expression, GPX4 expression, and their combination status were independent prognostic factors for disease-free survival. Analyses of the Kaplan-Meier Plotter database suggested that higher ACSL4 expression is related to better overall survival, and higher GPX4 expression is related to better distant metastasis-free survival. Pathway analyses revealed that ACSL4 and GPX4 might function in crucial pathways including apoptosis, autophagy, cell adhesion, lipid metabolism, etc. INTERPRETATION: This study revealed the critical value of ACSL4 and GPX4 serving as novel predictive and prognostic biomarkers for patients with breast cancer receiving neoadjuvant chemotherapy. It might be a novel strategy to induce ferroptosis to promote chemosensitivity. Future studies are required to elucidate the potential mechanisms. FUNDING This work was supported by Shanghai Natural Science Foundation [grant number 19ZR1431100], Clinical Research Plan of Shanghai Hospital Development Center [grant numbers SHDC2020CR3003A, 16CR3065B, and 12016231], Shanghai "Rising Stars of Medical Talent" Youth Development Program for Youth Medical Talents - Specialist Program [grant number 2018-15], Shanghai "Rising Stars of Medical Talent" Youth Development Program for Outstanding Youth Medical Talents [grant number 2018-16], Shanghai Collaborative Innovation Center for Translational Medicine [grant number TM201908], Multidisciplinary Cross Research Foundation of Shanghai Jiao Tong University [grant numbers YG2017QN49, ZH2018QNA42, and YG2019QNA28], Nurturing Fund of Renji Hospital [grant numbers PYMDT-002, PY2018-IIC-01, PY2018-III-15, and PYIII20-09], Science and Technology Commission of Shanghai Municipality [grant numbers 20DZ2201600 and 15JC1402700], and Shanghai Municipal Key Clinical Specialty.
Collapse
Affiliation(s)
- Rui Sha
- Department of Breast Surgery, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200127, People's Republic of China
| | - Yaqian Xu
- Department of Breast Surgery, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200127, People's Republic of China
| | - Chenwei Yuan
- Department of Breast Surgery, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200127, People's Republic of China
| | - Xiaonan Sheng
- Department of Breast Surgery, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200127, People's Republic of China
| | - Ziping Wu
- Department of Breast Surgery, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200127, People's Republic of China
| | - Jing Peng
- Department of Breast Surgery, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200127, People's Republic of China
| | - Yaohui Wang
- Department of Breast Surgery, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200127, People's Republic of China.
| | - Yanping Lin
- Department of Breast Surgery, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200127, People's Republic of China
| | - Liheng Zhou
- Department of Breast Surgery, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200127, People's Republic of China
| | - Shuguang Xu
- Department of Breast Surgery, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200127, People's Republic of China
| | - Jie Zhang
- Department of Breast Surgery, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200127, People's Republic of China
| | - Wenjin Yin
- Department of Breast Surgery, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200127, People's Republic of China.
| | - Jinsong Lu
- Department of Breast Surgery, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200127, People's Republic of China.
| |
Collapse
|
8
|
Mukama T, Kharazmi E, Sundquist K, Sundquist J, Fallah M. Risk-adapted starting age of breast cancer screening in women with a family history of ovarian or other cancers: A nationwide cohort study. Cancer 2021; 127:2091-2098. [PMID: 33620751 DOI: 10.1002/cncr.33456] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/15/2020] [Revised: 12/02/2020] [Accepted: 12/24/2020] [Indexed: 11/10/2022]
Abstract
BACKGROUND There is a lack of evidence-based recommendations for the age at which women with a family history of cancers other than breast cancer should start breast cancer screening. METHODS Using Swedish family cancer data sets, the authors conducted a nationwide cohort study including 5,099,172 Swedish women born after 1931 (follow-up, 1958-2015). Accounting for calendar time, they calculated the relative risk of breast cancer for women with a family history of a discordant cancer in 1 first-degree relative. Furthermore, the authors used 10-year cumulative risk to determine the ages at which women with a family history of discordant cancer reached risk thresholds at which women in the general population were recommended to start breast cancer screening. RESULTS A family history of cancer at 15 sites was associated with an increased risk of breast cancer. Among women younger than 50 years, the highest risk of breast cancer was observed for those with a family history of ovarian cancer (standardized incidence ratio, 1.44; 95% confidence interval, 1.26-1.64). In these women, the risk of breast cancer associated with a family history at other cancer sites ranged from 1.08-fold for prostate cancer to 1.18-fold for liver cancer. When breast cancer screening was recommended to be started at the age of 50 years for the general population, women with 1 first-degree relative with ovarian cancer attained the threshold risk for screening at the age of 46 years. Women with a family history of other discordant cancers did not reach the risk thresholds for screening at younger ages. CONCLUSIONS Many cancers showed familial associations with breast cancer, but women with a family history of these cancers (except for ovarian cancer) did not reach risk thresholds for screening at younger ages.
Collapse
Affiliation(s)
- Trasias Mukama
- Risk Adapted Prevention Group, Division of Preventive Oncology, National Center for Tumor Diseases, German Cancer Research Center, Heidelberg, Germany.,Department of Disease Control and Environmental Health, School of Public Health, College of Health Sciences, Makerere University, Kampala, Uganda
| | - Elham Kharazmi
- Risk Adapted Prevention Group, Division of Preventive Oncology, National Center for Tumor Diseases, German Cancer Research Center, Heidelberg, Germany.,Center for Primary Health Care Research, Lund University, Malmo, Sweden.,Statistical Genetics Group, Institute of Medical Biometry and Informatics, Heidelberg University, Heidelberg, Germany
| | - Kristina Sundquist
- Center for Primary Health Care Research, Lund University, Malmo, Sweden.,Department of Family Medicine and Community Health, Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, New York.,Center for Community-Based Healthcare Research and Education, Department of Functional Pathology, School of Medicine, Shimane University, Shimane, Japan
| | - Jan Sundquist
- Center for Primary Health Care Research, Lund University, Malmo, Sweden.,Department of Family Medicine and Community Health, Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, New York.,Center for Community-Based Healthcare Research and Education, Department of Functional Pathology, School of Medicine, Shimane University, Shimane, Japan
| | - Mahdi Fallah
- Risk Adapted Prevention Group, Division of Preventive Oncology, National Center for Tumor Diseases, German Cancer Research Center, Heidelberg, Germany.,Center for Primary Health Care Research, Lund University, Malmo, Sweden
| |
Collapse
|
9
|
Zheng Q, Ying Q, Ren Z, Zhang Q, Lu D, Wang H, Wei W. First-degree family history of prostate cancer is associated the risk of breast cancer and ovarian cancer. Medicine (Baltimore) 2021; 100:e23816. [PMID: 33530178 PMCID: PMC10545021 DOI: 10.1097/md.0000000000023816] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/13/2020] [Revised: 10/26/2020] [Accepted: 11/19/2020] [Indexed: 02/05/2023] Open
Abstract
ABSTRACT The evidence for associations between family history of prostate cancer and the risk of breast cancer and ovarian cancer is inconclusive. The first systematic review and meta-analysis of studies was conducted to assess the risk of breast cancer and ovarian cancer associated with a family history of prostate cancer.A literature search was conducted using MEDLINE, Embase and Web of science databases up to January 31, 2019. Data were screened and extracted independently by 2 reviewers. The pooled risk ratio (RR) and its 95% confidence interval (CI) were calculated using random-effects models. The GRADE approach was used to assess the quality of evidence.Nine observational studies including 8,011,625 individuals were included in the meta-analysis. The meta-analysis showed that family history of prostate cancer in first-degree relatives was associated with an increased risk of breast cancer (RR 1.12, 95%CI 1.09 to 1.14) with moderate quality evidence, subgroup analysis showed consistent results. Compared with no family history of prostate cancer, history of prostate cancer in first-degree relatives was associated with a slight risk of ovarian cancer (1.10, 95%CI 1.01 to 1.20) with moderate quality evidence. Family history of prostate cancer among sibling was associated with a 17% increased risk of ovarian cancer (95% CI 1.03 to 1.34), however, no significant association was found between family history of prostate cancer among parent and risk of ovarian cancer (RR 1.19, 95% CI 0.84 to 1.70).This review demonstrates that women with a family history of prostate cancer in first-degree relatives was associated with an increased risk of breast cancer and ovarian cancer. These findings may aid in screening, earlier detection and treatment of women with a family history of prostate cancer in first-degree relatives.
Collapse
Affiliation(s)
- QiongFei Zheng
- Department of Rehabilitation, Qianjiang Central Hospital of, Chongqing, Qianjiang
| | - Qinli Ying
- Department of Rehabilitation, Qianjiang Central Hospital of, Chongqing, Qianjiang
| | - ZhengJu Ren
- Department of Urology, The Second Affiliated Hospital, Chongqing Medical University
| | - Qin Zhang
- Department of Radiology, Chongqing Traditional Chinese Medicine Hospital, Chongqing
| | - DongLiang Lu
- Department of Urology, Shenzhen Hospital of Southern Medical University, Shenzhen
| | - HongBai Wang
- Department of Rehabilitation, Qianjiang Central Hospital of, Chongqing, Qianjiang
| | - WuRan Wei
- Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, Sichuan, China
| |
Collapse
|
10
|
Nichols HB, Graff M, Bensen JT, Lunetta KL, O'Brien KM, Troester MA, Williams LA, Young K, Hong CC, Yao S, Haiman CA, Ruiz-Narváez EA, Ambrosone CB, Palmer JR, Olshan AF. Genetic variants in anti-Müllerian hormone-related genes and breast cancer risk: results from the AMBER consortium. Breast Cancer Res Treat 2020; 185:469-478. [PMID: 32960377 PMCID: PMC7867570 DOI: 10.1007/s10549-020-05944-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/08/2020] [Accepted: 09/14/2020] [Indexed: 12/01/2022]
Abstract
PURPOSE Circulating anti-Müllerian hormone (AMH) levels are positively associated with time to menopause and breast cancer risk. We examined breast cancer associations with single nucleotide polymorphisms (SNPs) in the AMH gene or its receptor genes, ACVR1 and AMHR2, among African American women. METHODS In the AMBER consortium, we tested 65 candidate SNPs, and 1130 total variants, in or near AMH, ACVR1, and AMHR2 and breast cancer risk. Overall, 3649 cases and 4230 controls contributed to analyses. Odds ratios (OR) and 95% confidence intervals (CI) for breast cancer were calculated using multivariable logistic regression. RESULTS After correction for multiple comparisons (false-discovery rate of 5%), there were no statistically significant associations with breast cancer risk. Without correction for multiple testing, four candidate SNPs in ACVR1 and one near AMH were associated with breast cancer risk. In ACVR1, rs13395576[C] was associated with lower breast cancer risk overall (OR 0.84; 95% CI 0.72, 0.97) and for ER+ disease (OR 0.75; CI 0.62, 0.89) (p < 0.05). Rs1220110[A] and rs1220134[T] each had ORs of 0.89-0.90 for postmenopausal and ER+ breast cancer (p ≤ 0.03). Conversely, rs1682130[T] was associated with higher risk of ER+ breast cancer (OR 1.17; 95% CI 1.04, 1.32). Near AMH, rs6510652[T] had ORs of 0.85-0.90 for breast cancer overall and after menopause (p ≤ 0.02). CONCLUSIONS The present results, from a large study of African American women, provide limited support for an association between AMH-related polymorphisms and breast cancer risk and require replication in other studies.
Collapse
Affiliation(s)
- Hazel B Nichols
- Department of Epidemiology, University of North Carolina Gillings School of Global Public Health, 2104F McGavran-Greenberg Hall, Chapel Hill, NC, 27599-7435, USA.
| | - Mariaelisa Graff
- Department of Epidemiology, University of North Carolina Gillings School of Global Public Health, 2104F McGavran-Greenberg Hall, Chapel Hill, NC, 27599-7435, USA
| | - Jeannette T Bensen
- Department of Epidemiology, University of North Carolina Gillings School of Global Public Health, 2104F McGavran-Greenberg Hall, Chapel Hill, NC, 27599-7435, USA
| | - Kathryn L Lunetta
- Slone Epidemiology Center, Boston University, 72 E Concord Street, Boston, MA, 02118, USA
| | - Katie M O'Brien
- Epidemiology Branch, National Institute of Environmental Health Sciences, Durham, NC, USA
| | - Melissa A Troester
- Department of Epidemiology, University of North Carolina Gillings School of Global Public Health, 2104F McGavran-Greenberg Hall, Chapel Hill, NC, 27599-7435, USA
| | - Lindsay A Williams
- Department of Pediatrics, University of Minnesota, 2450 Riverside Avenue, Minneapolis, MN, 55454, USA
| | - Kristin Young
- Department of Epidemiology, University of North Carolina Gillings School of Global Public Health, 2104F McGavran-Greenberg Hall, Chapel Hill, NC, 27599-7435, USA
| | - Chi-Chen Hong
- Department of Cancer Prevention and Control, Roswell Park Cancer Institute, Elm & Carlton Streets, Buffalo, NY, 14263, USA
| | - Song Yao
- Department of Cancer Prevention and Control, Roswell Park Cancer Institute, Elm & Carlton Streets, Buffalo, NY, 14263, USA
| | - Christopher A Haiman
- Department of Preventive Medicine, University of Southern California Keck School of Medicine, Los Angeles, CA, USA
| | - Edward A Ruiz-Narváez
- Department of Nutritional Sciences, University of Michigan School of Public Health, Ann Arbor, MI, USA
| | - Christine B Ambrosone
- Department of Cancer Prevention and Control, Roswell Park Cancer Institute, Elm & Carlton Streets, Buffalo, NY, 14263, USA
| | - Julie R Palmer
- Slone Epidemiology Center, Boston University, 72 E Concord Street, Boston, MA, 02118, USA
| | - Andrew F Olshan
- Department of Epidemiology, University of North Carolina Gillings School of Global Public Health, 2104F McGavran-Greenberg Hall, Chapel Hill, NC, 27599-7435, USA
| |
Collapse
|
11
|
De-la-Cruz-Ku G, Luyo M, Morante Z, Enriquez D, Möller MG, Chambergo-Michilot D, Flores L, Luque R, Saavedra A, Eyzaguirre-Sandoval ME, Luján-Peche MG, Noel N, Calderon H, Razuri C, Fuentes HA, Cotrina JM, Neciosup SP, Araujo J, Lema A, Pinto J, Gomez HL, Valcarcel B. Triple-negative breast cancer in Peru: 2000 patients and 15 years of experience. PLoS One 2020; 15:e0237811. [PMID: 32833983 PMCID: PMC7444821 DOI: 10.1371/journal.pone.0237811] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/25/2020] [Accepted: 08/02/2020] [Indexed: 12/24/2022] Open
Abstract
Background Epidemiological studies commonly identify the clinical characteristics and survival outcomes of patients with breast cancer at five years. Our study aims to describe the sociodemographic, clinicopathological characteristics and determine the long-term event-free survival (EFS) and overall survival (OS) of a Peruvian population with triple-negative breast cancer. Methods We reviewed the medical records of new cases treated at a single institution in the period 2000–2014. The survival analysis included patients with stages I-IV. Survival estimates at 10 years were calculated with the Kaplan-Meier method and compared with the Log-rank test. We further used multivariate Cox regression analysis to calculate prognostic factors of recurrence and mortality. Results Among the 2007 patients included, the median age at diagnosis was 49 years (19–95 years). Most patients presented histologic grade III (68.7%), tumor stage II (34.2%), and III (51.0%) at diagnosis. Local and distant relapse was present in 31.9 and 51.4% of the patients, respectively. The most frequent sites of metastasis were the lungs (14.5%), followed by bone (9.7%), brain (9.6%), and liver (7.9%). The median follow-up was 153 months. At 3, 5, and 10 years, the EFS of the population was 55%, 49%, and 41%, respectively, while the OS was 64%, 56%, and 47%, respectively. Moreover, an N3 lymph node status was the most important prognostic factor for both disease relapse (HR: 2.54, 95% CI: 2.05–3.15) and mortality (HR: 2.51, 95% CI: 2.01–3.14) at ten years. An older age and higher T staging were associated with a worse OS, while patients who received radiotherapy and adjuvant chemotherapy had better survival rates. Conclusion The sociodemographic features of Peruvian patients with TNBC are similar to those of other populations. However, our population was diagnosed at more advanced clinical stages, and thus, EFS and OS were lower than international reports while prognostic factors were similar to previous studies.
Collapse
Affiliation(s)
| | | | - Zaida Morante
- Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru
| | | | - Mecker G. Möller
- Division of Surgical Oncology, University of Miami Miller School of Medicine, Jackson Memorial Hospital/Sylvester Comprehensive Cancer Center, Miami, FL, United States of America
| | - Diego Chambergo-Michilot
- School of Medicine, Universidad Científica del Sur (UCSUR), Lima, Peru
- Tau-RELAPED Group, Trujillo, Peru
| | - Lucero Flores
- School of Medicine, Universidad Científica del Sur (UCSUR), Lima, Peru
| | - Renato Luque
- School of Medicine, Universidad Científica del Sur (UCSUR), Lima, Peru
- Sociedad Científica de Estudiantes de Medicina Humana (SCIEM UCSUR), Lima, Peru
| | - Antonella Saavedra
- School of Medicine, Universidad Científica del Sur (UCSUR), Lima, Peru
- Sociedad Científica de Estudiantes de Medicina Humana (SCIEM UCSUR), Lima, Peru
| | - Miguel E. Eyzaguirre-Sandoval
- School of Medicine, Universidad Científica del Sur (UCSUR), Lima, Peru
- Sociedad Científica de Estudiantes de Medicina Humana (SCIEM UCSUR), Lima, Peru
| | - María G. Luján-Peche
- School of Medicine, Universidad Científica del Sur (UCSUR), Lima, Peru
- Sociedad Científica de Estudiantes de Medicina Humana (SCIEM UCSUR), Lima, Peru
| | - Naysha Noel
- School of Medicine, Universidad Científica del Sur (UCSUR), Lima, Peru
| | - Hafid Calderon
- School of Medicine, Universidad Científica del Sur (UCSUR), Lima, Peru
- Sociedad Científica de Estudiantes de Medicina Humana (SCIEM UCSUR), Lima, Peru
| | | | | | | | | | - Jhajaira Araujo
- Unidad de Investigación Básica y Translacional, Oncosalud-AUNA, Lima, Peru
| | - Alexandra Lema
- Health Sciences Faculty, Universidad de Cuenca, Cuenca, Ecuador
| | - Joseph Pinto
- Unidad de Investigación Básica y Translacional, Oncosalud-AUNA, Lima, Peru
| | - Henry L. Gomez
- Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru
| | - Bryan Valcarcel
- Milken Institute School of Public Health, The George Washington University, Washington, DC, United States of America
| |
Collapse
|
12
|
Breast Cancer Incidence and Mortality by Molecular Subtype: Statewide Age and Racial/Ethnic Disparities in New Jersey. CANCER HEALTH DISPARITIES 2019; 3:e1-e17. [PMID: 31440744 DOI: 10.9777/chd.2019.1012] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
The objective of this study was to assess breast cancer incidence and mortality rates by molecular subtype for cases diagnosed in New Jersey. Data on all primary, histologically confirmed, invasive breast cancers diagnosed among women between January 1, 2008 and December 31, 2013 were retrieved from the New Jersey State Cancer Registry. Age-adjusted incidence rates were calculated for each subtype, by ageandrace/ethnicity. Logistic regression models, Cox proportional hazards models, and Kaplan Meier curves were used to describe the relative risks for breast cancer incidence, mortality, and survival, respectively. In this population-based sample of 32,770 breast cancer cases, non-Hispanic Blacks (NHBs) had the highest triple-negative breast cancer (TNBC) incidence rate (17.8 per 100,000, 95% CI 16.5-19.2) compared to other races/ethnicities. NHBs had also higher odds of TNBC (OR 2.1, 95% CI 1.95-2.36) and higher hazards of death when diagnosed with TNBC (HR 1.28, 95% CI 1.05-1.56), luminal A (HR 1.64, 95% CI 1.41-1.91), or luminal B (HR 1.54, 95% CI 1.10-2.15) than non-Hispanic Whites (NHWs). Younger women (20-39 years) had higher odds of TNBC (OR 1.77, 95% CI 1.54-2.02) and luminal B (OR 1.56, 95% CI 1.35-1.80) compared to women 50-64 years; minority women had higher odds of non-luminal HER2-expressing and lower odds of luminal A than NHWs. TNBC was associated with the poorest survival rates. These findings highlight a need for enhanced screening to promote earlier diagnosis and improve breast cancer outcomes, particularly in minorities and younger women, which will be essential for achieving health equity.
Collapse
|
13
|
Sagna T, Bonora E, Ouedraogo MNL, Fusco D, Zoure AA, Bisseye C, Djigma F, Kafando JG, Zongo N, Douamba Z, Obiri-Yeboah D, Turchetti D, Pietra V, Lompo OM, Ouedraogo C, Seri M, Simpore J. Identification of BRCA1/2 p.Ser1613Gly, p.Pro871Leu, p.Lys1183Arg, p.Glu1038Gly, p.Ser1140Gly, p.Ala2466Val, p.His2440Arg variants in women under 45 years old with breast nodules suspected of having breast cancer in Burkina Faso. Biomol Concepts 2019; 10:120-127. [PMID: 31203256 DOI: 10.1515/bmc-2019-0015] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/05/2019] [Accepted: 05/07/2019] [Indexed: 01/18/2023] Open
Abstract
Breast cancer is the top cause of cancer mortality among women in the world and the second in Africa. The aims of this study were to: i) identify women with breast nodules suspected of having breast cancer ii) sequence the BRCA1 and BRCA2 genes and iii) screen mutations. From 2015 to 2016, 112 women aged from 35 to 44 years, who had come for consultation in the gynecology/obstetrics and the oncology department of the University Hospital Yalgado Ouedraogo, voluntarily agreed to participate to this study. Whole blood was collected from those with mammary nodules. The genomic DNA was extracted using Qiagen kit. FAST KAPA was used for genomic DNA amplification and the purified PCR products were analyzed by direct sequencing using Big Dye v1.1 and ABI 3730 automated sequencer. Nucleotides substitutions were determined. We identified BRCA1 SNPs rs1799966, rs799917, rs16942, rs16941, rs2227945, and BRCA2 SNPs rs169547, rs4986860. These identified variants are found mostly in cases of benign tumors of breast or ovarian cancer with familial history of breast cancer. This study in Burkina-Faso, is the basis for improved and more specific genetic testing, and suggests that additional genes contributing to an increased risk of breast cancer should be analyzed.
Collapse
Affiliation(s)
- Tani Sagna
- Centre de Recherche Biomoléculaire Pietro Annigoni (CERBA)/LABIOGENE, Université de Ouagadougou, 01 BP 364, Ouagadougou, Burkina Faso
| | - Elena Bonora
- U.O. Genetica Medica Dipartimento di Scienze Ginecologiche, Ostetriche, Pediatriche, Policlinico S. Orsola-Malpighi, Bologna, 902 D 40138, Italy
| | | | - Daniela Fusco
- U.O. Genetica Medica Dipartimento di Scienze Ginecologiche, Ostetriche, Pediatriche, Policlinico S. Orsola-Malpighi, Bologna, 902 D 40138, Italy
| | - Abdou Azaque Zoure
- Centre de Recherche Biomoléculaire Pietro Annigoni (CERBA)/LABIOGENE, Université de Ouagadougou, 01 BP 364, Ouagadougou, Burkina Faso.,Institut de Recherche en Sciences de la Santé (IRSS), Ouagadougou, 03 BP 7192, Burkina Faso
| | - Cyrille Bisseye
- Centre de Recherche Biomoléculaire Pietro Annigoni (CERBA)/LABIOGENE, Université de Ouagadougou, 01 BP 364, Ouagadougou, Burkina Faso.,Département de Biologie, Faculté des Sciences Université des Sciences et Techniques de Masuku (USTM), BP 934 de Masuku, Gabon
| | - Florencia Djigma
- Centre de Recherche Biomoléculaire Pietro Annigoni (CERBA)/LABIOGENE, Université de Ouagadougou, 01 BP 364, Ouagadougou, Burkina Faso
| | | | - Nayi Zongo
- Hôpital Saint Camille, Ouagadougou, 09 BP 444, Burkina Faso
| | - Zoenabo Douamba
- Centre de Recherche Biomoléculaire Pietro Annigoni (CERBA)/LABIOGENE, Université de Ouagadougou, 01 BP 364, Ouagadougou, Burkina Faso
| | - Dorcas Obiri-Yeboah
- Department of Microbiology and Immunology, School of Medical Sciences, University of Cape Coast, P. O. Box 5007, Cape Coast, Ghana
| | - Daniela Turchetti
- U.O. Genetica Medica Dipartimento di Scienze Ginecologiche, Ostetriche, Pediatriche, Policlinico S. Orsola-Malpighi, Bologna, 902 D 40138, Italy
| | - Virginio Pietra
- Centre de Recherche Biomoléculaire Pietro Annigoni (CERBA)/LABIOGENE, Université de Ouagadougou, 01 BP 364, Ouagadougou, Burkina Faso.,Hôpital Saint Camille, Ouagadougou, 09 BP 444, Burkina Faso
| | - Olga Melanie Lompo
- Centre Hospitalier Universitaire Yalgado Ouedraogo (CHU/YO), Ouagadougou, 03 BP 7022 Burkina Faso
| | - Charlemagne Ouedraogo
- Centre Hospitalier Universitaire Yalgado Ouedraogo (CHU/YO), Ouagadougou, 03 BP 7022 Burkina Faso
| | - Marco Seri
- U.O. Genetica Medica Dipartimento di Scienze Ginecologiche, Ostetriche, Pediatriche, Policlinico S. Orsola-Malpighi, Bologna, 902 D 40138, Italy
| | | |
Collapse
|
14
|
Márquez-Rodas I, Pollán M, Escudero MJ, Ruiz A, Martín M, Santaballa A, Martínez del Prado P, Batista N, Andrés R, Antón A, Llombart A, Fernandez Aramburu A, Adrover E, González S, Seguí MA, Calvo L, Lizón J, Rodríguez Lescure Á, Ramón y Cajal T, Llort G, Jara C, Carrasco E, López-Tarruella S. Frequency of breast cancer with hereditary risk features in Spain: Analysis from GEICAM "El Álamo III" retrospective study. PLoS One 2017; 12:e0184181. [PMID: 28985233 PMCID: PMC5630120 DOI: 10.1371/journal.pone.0184181] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/26/2016] [Accepted: 08/16/2017] [Indexed: 11/18/2022] Open
Abstract
PURPOSE To determine the frequency of breast cancer (BC) patients with hereditary risk features in a wide retrospective cohort of patients in Spain. METHODS a retrospective analysis was conducted from 10,638 BC patients diagnosed between 1998 and 2001 in the GEICAM registry "El Álamo III", dividing them into four groups according to modified ESMO and SEOM hereditary cancer risk criteria: Sporadic breast cancer group (R0); Individual risk group (IR); Familial risk group (FR); Individual and familial risk group (IFR) with both individual and familial risk criteria. RESULTS 7,641 patients were evaluable. Of them, 2,252 patients (29.5%) had at least one hereditary risk criteria, being subclassified in: FR 1.105 (14.5%), IR 970 (12.7%), IFR 177 (2.3%). There was a higher frequency of newly diagnosed metastatic patients in the IR group (5.1% vs 3.2%, p = 0.02). In contrast, in RO were lower proportion of big tumors (> T2) (43.8% vs 47.4%, p = 0.023), nodal involvement (43.4% vs 48.1%, p = 0.004) and lower histological grades (20.9% G3 for the R0 vs 29.8%) when compared to patients with any risk criteria. CONCLUSIONS Almost three out of ten BC patients have at least one hereditary risk cancer feature that would warrant further genetic counseling. Patients with hereditary cancer risk seems to be diagnosed with worse prognosis factors.
Collapse
Affiliation(s)
- Iván Márquez-Rodas
- Servicio de Oncología Médica, Hospital General Universitario Gregorio Marañón, Madrid, Spain
- Spanish Breast Cancer Research Group (GEICAM), San Sebastian de los Reyes, Spain
- * E-mail:
| | - Marina Pollán
- Spanish Breast Cancer Research Group (GEICAM), San Sebastian de los Reyes, Spain
- Instituto de Salud Carlos III, Madrid, Spain
| | - María José Escudero
- Spanish Breast Cancer Research Group (GEICAM), San Sebastian de los Reyes, Spain
| | - Amparo Ruiz
- Spanish Breast Cancer Research Group (GEICAM), San Sebastian de los Reyes, Spain
- Servicio de Oncología Médica, Instituto Valenciano de Oncología, Valencia, Spain
| | - Miguel Martín
- Servicio de Oncología Médica, Hospital General Universitario Gregorio Marañón, Madrid, Spain
- Spanish Breast Cancer Research Group (GEICAM), San Sebastian de los Reyes, Spain
| | - Ana Santaballa
- Spanish Breast Cancer Research Group (GEICAM), San Sebastian de los Reyes, Spain
- Servicio de Oncología Médica, Hospital Universitari i Politècnic La Fe, Valencia, Spain
| | - Purificación Martínez del Prado
- Spanish Breast Cancer Research Group (GEICAM), San Sebastian de los Reyes, Spain
- Servicio de Oncología Médica, Hospital de Basurto-Osakidetza, Bilbao, Spain
| | - Norberto Batista
- Spanish Breast Cancer Research Group (GEICAM), San Sebastian de los Reyes, Spain
- Servicio de Oncología Médica, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain
| | - Raquel Andrés
- Spanish Breast Cancer Research Group (GEICAM), San Sebastian de los Reyes, Spain
- Servicio de Oncología Médica, Hospital Lozano Blesa, Zaragoza, Spain
| | - Antonio Antón
- Spanish Breast Cancer Research Group (GEICAM), San Sebastian de los Reyes, Spain
- Servicio de Oncología Médica, Hospital Universitario Miguel Servet, Zaragoza, Spain
| | - Antonio Llombart
- Spanish Breast Cancer Research Group (GEICAM), San Sebastian de los Reyes, Spain
- Servicio de Oncología Médica, Hospital Arnau de Vilanova, Valencia, Spain
| | - Antonio Fernandez Aramburu
- Spanish Breast Cancer Research Group (GEICAM), San Sebastian de los Reyes, Spain
- Sección de Oncología Médica, Complejo Universitario de Albacete, Albacete, Spain
| | - Encarnación Adrover
- Spanish Breast Cancer Research Group (GEICAM), San Sebastian de los Reyes, Spain
- Sección de Oncología Médica, Complejo Universitario de Albacete, Albacete, Spain
| | - Sonia González
- Spanish Breast Cancer Research Group (GEICAM), San Sebastian de los Reyes, Spain
- Servicio de Oncología Médica, Servicio de Oncología Médica, Hospital Mútua de Terrassa, Barcelona, Spain
| | - Miguel Angel Seguí
- Spanish Breast Cancer Research Group (GEICAM), San Sebastian de los Reyes, Spain
- Servicio de Oncología Médica, Hospital de Sabadell-Consorcio Sanitario Parc Taulì de Sabadell, Barcelona, Spain
| | - Lourdes Calvo
- Spanish Breast Cancer Research Group (GEICAM), San Sebastian de los Reyes, Spain
- Servicio de Oncología Médica, Complejo Hospitalario Universitario A Coruña, A Coruña, Spain
| | - José Lizón
- Spanish Breast Cancer Research Group (GEICAM), San Sebastian de los Reyes, Spain
- Servicio de Oncología Médica, Hospital Universitario Sant Joan, Alicante, Spain
| | - Álvaro Rodríguez Lescure
- Spanish Breast Cancer Research Group (GEICAM), San Sebastian de los Reyes, Spain
- Servicio de Oncología Médica, Hospital General Universitario de Elche, Elche, Spain
| | - Teresa Ramón y Cajal
- Spanish Breast Cancer Research Group (GEICAM), San Sebastian de los Reyes, Spain
- Servicio de Oncología Médica, Hospital de Sant Pau, Barcelona, Spain
| | - Gemma Llort
- Spanish Breast Cancer Research Group (GEICAM), San Sebastian de los Reyes, Spain
- Unitat de Consell Genetic, Institut Oncologic del Valles, Terrasa, Spain
| | - Carlos Jara
- Spanish Breast Cancer Research Group (GEICAM), San Sebastian de los Reyes, Spain
- Unidad de Oncología, Hospital Universitario Fundación Alcorcón, Alcorcon, Madrid, Spain
| | - Eva Carrasco
- Spanish Breast Cancer Research Group (GEICAM), San Sebastian de los Reyes, Spain
| | - Sara López-Tarruella
- Servicio de Oncología Médica, Hospital General Universitario Gregorio Marañón, Madrid, Spain
- Spanish Breast Cancer Research Group (GEICAM), San Sebastian de los Reyes, Spain
| |
Collapse
|
15
|
Thakur KK, Bordoloi D, Kunnumakkara AB. Alarming Burden of Triple-Negative Breast Cancer in India. Clin Breast Cancer 2017; 18:e393-e399. [PMID: 28801156 DOI: 10.1016/j.clbc.2017.07.013] [Citation(s) in RCA: 88] [Impact Index Per Article: 12.6] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/15/2017] [Accepted: 07/16/2017] [Indexed: 01/11/2023]
Abstract
Breast cancer is the most prevalent cancer among women worldwide. Among the different breast cancer subtypes, triple-negative breast cancer (TNBC), which is more prevalent among younger age women, is the most aggressive form. Numerous clinicopathologic studies performed throughout the world strongly support the utterly poor prognoses and high recurrence rate of TNBC. The present report details a thorough data survey from Google and PubMed on the burden of TNBC worldwide and other associated factors, with special emphasis on its ever increasing incidence among Indian women. Our analysis revealed that the proportion of TNBC ranges from 6.7% to 27.9% in different countries, with the highest reported percentage in India among all, followed by Indonesia, Algeria, and Pakistan. Most of the other countries (Netherlands, Italy, London, Germany) had a TNBC incidence less than the mean level (ie, 15%). The high incidence of TNBC in the Indian population is associated with vivid risk factors, which primarily include lifestyle, deprivation status, obesity, family history, high mitotic indexes, and BRCA1 mutations. The treatment of TNBC is greatly hampered due to the lack of targeted therapies. Hence, it requires earnest attention towards extensive research for the prevention and development of treatment modalities with high efficacy.
Collapse
Affiliation(s)
- Krishan K Thakur
- Cancer Biology Laboratory & DBT-AIST International Laboratory for Advanced Biomedicine (DAILAB), Department of Biosciences and Bioengineering, Indian Institute of Technology Guwahati, Assam, India
| | - Devivasha Bordoloi
- Cancer Biology Laboratory & DBT-AIST International Laboratory for Advanced Biomedicine (DAILAB), Department of Biosciences and Bioengineering, Indian Institute of Technology Guwahati, Assam, India
| | - Ajaikumar B Kunnumakkara
- Cancer Biology Laboratory & DBT-AIST International Laboratory for Advanced Biomedicine (DAILAB), Department of Biosciences and Bioengineering, Indian Institute of Technology Guwahati, Assam, India.
| |
Collapse
|
16
|
Williams LA, Olshan AF, Hong CC, Bandera EV, Rosenberg L, Cheng TYD, Lunetta KL, McCann SE, Poole C, Kolonel LN, Palmer JR, Ambrosone CB, Troester MA. Alcohol Intake and Breast Cancer Risk in African American Women from the AMBER Consortium. Cancer Epidemiol Biomarkers Prev 2017; 26:787-794. [PMID: 28420652 PMCID: PMC5568081 DOI: 10.1158/1055-9965.epi-16-0792] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/07/2016] [Revised: 01/18/2017] [Accepted: 01/19/2017] [Indexed: 12/13/2022] Open
Abstract
Background: Alcohol is a recognized risk factor for invasive breast cancer, but few studies involve African American women.Methods: The current analysis included 22,338 women (5,108 cases of invasive breast cancer) from the African American Breast Cancer Epidemiology and Risk (AMBER) Consortium. The association between number of alcoholic drinks per week (dpw) and breast cancer was estimated using logistic regression, adjusting for potential confounders, and stratifying by breast cancer subtype.Results: Approximately 35% of controls were current drinkers at interview. Women who reported current drinking of ≥14 dpw had an elevated risk of breast cancer compared with light drinkers (>0-<4 dpw) [adjusted OR (ORadj), 1.33; 95% confidence interval (CI), 1.07-1.64]. We observed elevated risk among women drinking ≥7 dpw for ER - [ORadj, 1.31; 95% CI, 1.00-1.72], PR - [ORadj, 1.28; 95% CI, 1.00-1.63], HER2 - [ORadj, 1.36; 95% CI, 1.09-1.70], and triple-negative [ORadj, 1.39; 95% CI, 0.98-2.00] molecular subtype. Among receptor-positive cases, ORs remained elevated but attenuated relative to receptor-negative cases. Sensitivity analysis of age-defined windows of exposure (<30 years, 30-49, 50+ years of age) did not reveal variation in patterns of association. Risk associated with alcohol intake did not vary significantly by oral contraceptive use, smoking status, or menopausal status.Conclusions: Among African American women, similar to women of European descent, drinking ≥7 alcoholic dpw was associated with an increased risk of breast cancer regardless of subtype.Impact: Alcohol intake is a modifiable risk factor for breast cancer, and reduced intake among African American women should be encouraged. Cancer Epidemiol Biomarkers Prev; 26(5); 787-94. ©2017 AACR.
Collapse
Affiliation(s)
- Lindsay A Williams
- Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina
| | - Andrew F Olshan
- Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina
| | - Chi-Chen Hong
- Department of Cancer Prevention and Control, Roswell Park Cancer Institute, Buffalo, New York
| | - Elisa V Bandera
- Cancer Prevention and Control Program, Rutgers Cancer Institute of New Jersey, Rutgers, The State University of New Jersey, New Brunswick, New Jersey
| | - Lynn Rosenberg
- Slone Epidemiology Center, Boston University, Boston, Massachusetts
| | - Ting-Yuan David Cheng
- Department of Cancer Prevention and Control, Roswell Park Cancer Institute, Buffalo, New York
| | - Kathryn L Lunetta
- Department of Biostatistics, Boston University School of Public Health, Crosstown Center, Boston, Massachusetts
| | - Susan E McCann
- Department of Cancer Prevention and Control, Roswell Park Cancer Institute, Buffalo, New York
| | - Charles Poole
- Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina
| | - Laurence N Kolonel
- Cancer Epidemiology Program, University of Hawaii Cancer Center, Honolulu, Hawaii
| | - Julie R Palmer
- Slone Epidemiology Center, Boston University, Boston, Massachusetts
| | - Christine B Ambrosone
- Department of Cancer Prevention and Control, Roswell Park Cancer Institute, Buffalo, New York
| | - Melissa A Troester
- Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
| |
Collapse
|
17
|
Family history of cancer other than breast or ovarian cancer in first-degree relatives is associated with poor breast cancer prognosis. Breast 2017; 32:130-134. [PMID: 28178607 DOI: 10.1016/j.breast.2017.01.016] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/22/2016] [Revised: 01/25/2017] [Accepted: 01/27/2017] [Indexed: 12/25/2022] Open
Abstract
OBJECTIVE Whether a first-degree family history of others cancers (FHOC) than breast or ovarian cancer (BOC) is associated with breast cancer prognosis remains unknown. Thus, the aim of the present study was to clarify this issue. METHODS Women who were diagnosed with invasive breast cancer at the Renmin Hospital of Wuhan University from 2010 to 2013 were included in the study. The demographic and clinicopathological characteristics of these patients were extracted. FHOC was considered positive for any patient who had a relative who had been diagnosed with cancer other than BOC. Disease-free survival (DFS) was calculated based on the date of diagnosis. DFS was analyzed using the Cox proportional hazards model. RESULTS A total of 434 breast cancer patients were included in this study. Among these patients, 61 (14.06%) had a positive FHOC in first-degree relatives. Patients with a positive FHOC tended to have HER2-positive breast cancer (p = 0.03). In the survival analysis, FHOC was associated with poor DFS in both univariate (HR = 2.21 (1.28-3.83), 95% CI: 1.28-3.83, p < 0.01) and multivariate (HR = 2.50, 95% CI: 1.24-5.04, p = 0.01) analyses, especially in patients with luminal A subtypes. CONCLUSION The results demonstrated an increased risk of recurrence in breast cancer patients with FHOC, especially in patients with luminal A subtype.
Collapse
|